• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.87 -0.53 (-1.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
January 16, 2026
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
January 13, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Provides Corporate Update and 2026 Outlook
January 12, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
November 06, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
November 04, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Third Quarter 2025 Financial Results
October 30, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Third Quarter 2025 Financial Results
October 23, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
October 17, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
September 26, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
September 10, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
September 03, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
August 27, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Second Quarter 2025 Financial Results
August 06, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
August 05, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Second Quarter 2025 Financial Results
July 30, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
July 06, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
July 01, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 30, 2025
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
June 28, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 26, 2025
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 25, 2025
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 24, 2025
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 23, 2025
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap